[English]  [Pусский]  [中文]  
 
ctt-journal > Vinogradov et al. (Abstract)

Vinogradov et al. (Abstract)

Cellular Therapy and Transplantation (CTT), Vol. 2, No. 5, 2009
doi: 10.3205/ctt-2009-No5-abstract32
© The Authors. This abstract is provided under the following license:
Creative Commons Attribution 3.0 Unported


Abstract accepted for "Joint EBMT Pediatric Working Party – 3rd Raisa Gorbacheva Memorial Meeting on Hematopoietic Stem Cell Transplantation", Saint Petersburg, Russia, September 17–20, 2009

pdf version

Comparative analysis of acute myeloid leukemia treatment results in the Sverdlovsk Regional Clinical Hospital №1

Alexander V. Vinogradov, Tatiana S. Konstantinova, Alexander F. Tomilov, Vladimir A. Shalaev, Elena V. Chepuryaeva, Julia V. Sveshnikova, Leonid N. Sharov, Natalia V. Vinogradova

Ural State Medical Academy, Sverdlovsk Regional Clinical Hospital N1, Ekaterinburg, Russia

Correspondence: Ural State Medical Academy, Sverdlovsk Regional Clinical Hospital N1, Ekaterinburg, Russia, Gurzufskaya Str., 11/1-4, 620086 Ekaterinburg, Russia, Phone: +7 (343) 2683648, Fax: +7 (343) 2120146, E-mail: vinogradov-av@spam is badyandex.ru

Abstract

Aim: To estimate the prognostic significance of cytogenetic abnormalities in acute myeloid leukemia (AML) patients—who were treated according to the following chemotherapy protocols: RHSC AML 01.99, 01.01, and >60 years old.

Methods: A total of 125 AML pts were treated with RHSC AML 01.99, 01.01 and >60 y.o. protocols from 1999 to 2008. The distribution of pts by protocol was as follows: AML 01.99 – 16, AML 01.01 – 84, and AML >60 y.o. – 25. The cytogenetic variants of AML according to the protocols are presented in Table 1.

Table 1.

Protocol t(8;21), % inv(16), % 46,xy/46,xx, % Others, %
AML 01.01 20.3 18.8 26.1 34.8
AML 01.99 - 38.5 30.8 30.8
AML > 60 y.o. - 27.8 22.2 50.0


Results:
The results of the comparative analysis of treatment results are presented in Table 2.

Table 2.

Characteristics AML 01.01 AML 01.99 AML > 60 y.o.
Early death    
n 8 1 4
% 9.5 6.3 16.0
Resistance    
n 28 2 4
% 33.3 12.5 16.0
Complete remission    
n 48 13 17
% 57.1 81.3 68.0
Relapses    
n 18 5 5
% 34.6 38.5 29.4
Remission death    
n 7 2 1
% 13.5 15.4 5.9


The results of the comparative analysis of treatment according to cytogenetics are presented in Table 3.

Table 3.

Characteristics t(8;21) Inv(16) 46,xy/46,xx t(9;22), abn(11q), etc. Others
Early death - 8.7 23.1 13.0 -
Resistance 7.7 13.0 23.1 43.5 61.5
Complete remission 92.3 78.3 57.7 43.5 38.5
Relapses 50.0 11.1 66.7 40.0 40.0
Remission death 16.7 11.1 13.3 10.0 20.0


The comparative analysis of overall survival (OS) and relapse-free survival (RFS) of AML pts according to cytogenetics is presented in Figures 1 and 2.

Figure 1. Actuarial probability of AML pts’ OS according to cytogenetics

Figure 2. Actuarial probability of AML pts’ RFS according to cytogenetics


Thus, in AML pts treated by RHSC AML 01.99, 01.01, and >60 y.o. protocols, only inv(16) has a favorable prognostic significance. All other cytogenetic subtypes were associated with unfavorable prognosis.

Keywords: acute myeloid leukemia, treatment, cytogenetic abnormalities

<-- Previous abstract        Contents        Next abstract -->